로딩 중…
StockDiggingStockDigging

BioNote, Inc.

377740· KOSPI
₩4,640+0.22%
2026-06-19

Price Chart

BioNote, Inc.-9.90%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap472.75B KRW
Revenue122.44B KRW
Net Income-50.23B KRW
Total Assets1.61T KRW
Net Assets1.54T KRW
Employees313
Value
P/B0.31x
P/S3.86x
EV/EBITDA167.68x
FCF Yield1.33%
Profitability
ROE-3.26%
ROA-3.12%
Op. Margin2.03%
Revenue Growth14.49%
Earnings Growth925.36%
Financial Health
Debt Ratio104.40%
Total Debt0 KRW
FCF6.27B KRW
Cash55.08B KRW
Current Ratio10.15x
Net Debt/EBITDA-22.11x
Dividend
Div. Yield4.92%
Div. Growth14.00%
Performance
1Y Return-9.90%
1M Return-7.11%
From 52W High-26.58%
1Y MDD-27.45%
Trading
Volume77,830 shares
Foreign Own.0.48%
Per Share
EPS-492 KRW
BPS15,288 KRW

Company Info

CEO 조병기
Employees 313
Founded 2003
HQ 경기도 화성시, KR

Bionote, established in 2003 and listed on the KOSPI market in 2022, specializes in animal diagnostic products and bio-content. Utilizing its unique recombinant antigen and antibody manufacturing technology, it produces and distributes diverse diagnostic products and bio-content across over 80 countries. The company is expanding its business into molecular and biochemical diagnostics. It aims to increase global market share by launching fully automated point-of-care diagnostic devices.